Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05096390
Title Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC (PAXIPEM)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Centre Leon Berard
Indications

papillary renal cell carcinoma

Therapies

Axitinib + Pembrolizumab

Axitinib

Age Groups: senior | adult
Covered Countries FRA


No variant requirements are available.